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Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive 
breast cancer and for prostate cancer. Serum levels concentrations of oestradiol and testosterone are 
controlled by the hypothalamic–-pituitary–-gonadal pathway. Oestradiol is produced in premenopausal 
women from the ovaries, and in postmenopausal women by peripheral conversion of adrenal androgens 
by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is 
primarily achieved by castration. In postmenopausal women, selective oestrogen receptor modulators 
(e.g. tamoxifen) or aromatase inhibitors are used. Hormone therapy can be used to reduce the size of the 
primary cancer beforeprior to radical surgery or radiotherapy, or to reduce the risk of recurrence. 
Hormone therapy is highly effective in patients with locally advanced or metastatic disease, with high 
response rates. Most patients eventually relapse with hormone-refractory disease and maycan be offered 
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•Breast cancer is highly sensitive to hormonal therapies, with response rates related to oestrogen 
receptor and progesterone receptor status 
•Recurrence is managed with a switch to other hormonal agents or addition of novel pathway inhibitors, 
which has an improvesd efficacy in metastatic breast cancer 
•Metastatic pProstate cancer has an almost 100% response rate to initial androgen deprivation therapy 
(medical castration). Relapse is , but relapse is inevitable and managed with addition , when patients are 
switched toof more active hormonal agents or chemotherapy 
•Mechanisms Of Resistance to these newer agents in prostate cancer are is emerging and should lead 
tostimulate further therapeutic approaches and improvements in outcome 
•Patients can be on hormonal therapy for many years and awareness, prevention and management of 
late effects is critical 
 
 
Background (see also Breast Cancer on pages 42–46 and Prostate Cancer on pages 47–51 of this 
issue) 
This paper will concentrates on the management of breast and prostate cancers in which the impact of 
hormone therapy is most clinically significant (see also Breast Cancer on pages xx–xx and Prostate 
Cancer on pages xx–xx of this issue). Increased exposure to endogenous or exogenous oestrogens 
maymay be linked to the development of breast cancer (Table 1). However, there is no evidence that 
exposure to androgens is important in the development of prostate cancer. 
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In 1896 Beatson demonstrated that surgical oophorectomy resulted in tumour regression in 
premenopausal women with metastatic breast cancer. Charles Huggins was awarded the Nobel Prize for 
medicine in 1966 after his discovery that surgical orchidectomy was a successful treatment for 
metastatic prostate cancer. 
 
Hormone synthesis 
Oestrogen is synthesized from cholesterol in the parafollicular ovaries in premenopausal women via the 
hypothalamic-pituitary-gonadal axis (Figure 1), and in the adrenals in postmenopausal women. In 
premenopausal women, oestrogen production is cyclical: gonadotrophin-releasing hormone (GnRH) is 
released from the hypothalamus with a circadian rhythm under direct feedback from circulating 
hormones. GnRH reacts with anterior pituitary receptors, leading to the release of luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH); these stimulate the ovaries to produce oestradiol. 
In postmenopausal women, the main site of oestrogen synthesis is adipose tissue. Here, adrenal 
androgens (e.g. androstenedione) are converted by aromatase to oestrone. Oestrone is then converted to 
oestradiol by 17β-OH dehydrogenase. Postmenopausal synthesis varies depending on environmental 
and genetic factors (e.g. obesity). 
In men, the main circulating androgen is testosterone, 90% of which is produced by the testicular 
Leydig cells under control of the hypothalamic–pituitary axis, as above. The remaining circulating 
androgens (e.g. dihydroxyandrostenedione) are produced in the adrenal cortex and the prostate itself 
from cholesterol. Testosterone is metabolized by 5α-reductase within the prostate to the more biologically 
active dihydrotestosterone, which acts as the ligand for the androgen receptor (AR). 
 
Hormone receptors 
In breast cancer, approximately 80% of postmenopausal women and 50% of premenopausal women 
have hormone receptor-positive disease. The degree of positivity is defined by the level of expression of 
both oestrogen (ER) and progesterone receptors, which are routinely measured immunohistochemically 
in newly diagnosed women. Systemic treatment and, to some extent, prognosis is guided by 
hormone receptor status.1 
In contrast, measurement of ARs is not currently routinely performed in prostate cancer as there 
is no or prognostic therapeutic value. However, recent work has shown that AR variants (e.g. ARv7) 
underlie resistance to castration, predict response to alternative AR-targeting agents and can be detected 
in both tumour tissue and circulating tumour cells.  
 
Hormone therapy in breast cancer 
Ovarian ablation 
In premenopausal women, oestrogen suppression is achieved by chemical ablation, radiation to the 
ovaries or surgical oophorectomy. Chemical ablation is reversible and achieved using a GnRH (or LH-
releasing hormone (LHRH)) agonist (GnRHa, LHRHa) such as goserelin or leuprorelin, usually as a 
monthly depot injection.  
 
Other hormonal agents in breast cancer 
An increasing number of hormonal treatment options are available to treat breast cancer. A description of 
the different drugs licensed in the UK is given in Table 2. The most commonly used treatments 
include tamoxifen and aromatase inhibitors (AIs). 
 
Tamoxifen: this is a selective oestrogen receptor modulator with complex actions on ERs, acting 
predominantly as an antagonist, with weak agonist effects. In ER-positive early breast cancer, 5 years 
of tamoxifen after surgery reduces the annual recurrence rate by 41% and annual mortality rate by 34%.2 
There is evidence of a reduction in breast cancer recurrence and mortality by continuing tamoxifen in ER-
positive disease for 10 years rather than stopping at 5 years. Tamoxifen can be used in 
premenopausal and postmenopausal women. The main adverse effects are hot flushes, night sweats and 
vaginal discharge. There is an increased risk of thrombotic events. Vaginal bleeding should be promptly 
evaluated because of the increased risk of endometrial cancer.  
 
Aromatase inhibitors: several Phase III clinical trials have established third-generation AIs as the new 
gold standard in the adjuvant hormonal treatment of receptor-positive early breast cancer. They are 
Commented [CMW3]: AQ: presumably this is licensed in 
the UK? 
contraindicated in premenopausal women unless ovarian suppression has been induced. There are three 
main approaches with early breast cancer: 
•up-front use for 5 years 
•planned or unplanned switching, i.e. use of AIs for 2–3 years after 2–3 years of tamoxifen 
•extended therapy, i.e. after 5 years' use of tamoxifen. 
The main toxicities of AIs are hot flushes, arthralgia, reduced bone mineral density and increased 
risk of fractures. Women at risk of osteoporosis should be carefully monitored or treated with 
bisphosphonates where necessary.3 A new approach in treating metastatic disease is the use of AIs in 
combination with pathway inhibitors such as cyclin-dependent kinases (CDKs). CDK4/6 inhibitors such 
as palbociclib, ribociclib and abemaciclib used in combination with letrozole or fulvestrant 
have shown an improvement in progression-free survival and have become the treatment of choice 
providing the increased toxicity is manageable. 
 
Main indications for hormonal therapy in breast cancer 
•As a neoadjuvant to reduce the size of the primary tumour, making it operable or reducing the extent of 
surgery, for example from mastectomy to wide local excision. 
•As an adjuvant after surgery to reduce the risk of recurrence and improve survival . 
•As a palliative treatment to shrink and control large inoperable cancers . 
•As a palliative treatment for metastatic disease to prolong and improve quality of life. 
 
Hormone therapy in prostate cancer 
Androgen deprivation therapy 
Serum testosterone is reduced to castrate concentrations by surgical or chemical castration, with 
an LHRHa or the newer LHRH antagonists. Castration can lead to hot flushes, sweats and reduced libido. 
Patients can notice reduced muscle mass, reduced strength and weight gain. There can be loss of  
bone mineral density and there are concerns of an increased risk of fatal cardiac events.  
Initial use of LHRHa results in a surge in serum testosterone, which can worsen symptoms: 
all patients should take oral antiandrogens for at least 3 weeks, starting 1–2 weeks before the 
initial LHRHa injection. Degarelix is an LHRH antagonist that rapidly achieves castrate 
concentrations of testosterone without a testosterone flare. It should be used in emergency situations 
such as new diagnoses presenting with metastatic spinal cord compression or renal tract obstruction . 
Hormonal therapy is not curative and metastatic patients inevitably relapse at some stage; this is 
termed ‘castrate-refractory prostate cancer’ (CRPC). 
 
Other hormonal agents in prostate cancer 
The key agents used in the management of prostate cancer are described in Table 3. 
Bicalutamide is a non-steroidal antiandrogen and competitive AR inhibitor. It can be used as an 
alternative to an LHRHa, with a lower incidence of erectile dysfunction, but equivalent efficacy has not 
been proven. It can be added to an LHRHa as a low-toxicity agent for 
CRPC, with a response rate up to 66%. 
Abiraterone acetate, enzalutamide, apalutamide and darolutamide are newer agents 
providing much greater AR suppression. Trials have shown prolongation of overall survival in combination 
with androgen deprivation therapy in hormone-sensitive metastatic prostate cancer, such that 
median survival is now >5 years. There is also evidence improved progression-free and/or overall 
survival in both non-metastatic and metastatic CRPC.4,5 Abiraterone is an androgen synthesis inhibitor 
blocking adrenal and prostatic production of androgens. Enzalutamide, apalutamide and darolutamide are 
potent AR inhibitors that also block the translocation of activated AR to the nucleus and interactions 
between AR and DNA.  
Corticosteroids are highly active in CRPC but have no proven survival advantage and are not 
licensed in the UK for use in prostate cancer. Long-term use is associated with typical glucocorticoid 
adverse effects, such as proximal myopathy and reduced bone mineral density, and patients require 
regular review.3 
 
Main indications for hormonal treatment in prostate cancer 
•Neoadjuvant therapy before radiotherapy to improve local and biochemical (prostate-specific 
antigen) control in patients with locally advanced tumours. 
•As an adjuvant after radiotherapy to improve overall survival in high-risk disease. 
•Palliatively for metastatic hormone-sensitive and CRPC. Almost 
all patients respond to initial hormonal therapy, with a median response duration of 




Resistance develops in nearly all patients with metastatic breast and prostate cancer who initially respond 
to hormone therapy, resulting in disease progression. The molecular causes of resistance are complex, 
varied and not well understood. Mechanisms may include increased sensitivity of hormone receptors, 
hormone receptor variants, pathway activation without exposure to hormones (constitutive activation) or 
upregulated downstream survival pathways. As these become better characterized, new agents are 
being developed, trialled and introduced into practice.  
Hormonal risks for breast cancer 
Risk factors Protective factors 
Early menarche Breastfeeding 










Key hormonal therapies in breast cancer 
Drug Type Dose/route Mode of action 
Tamoxifen Anti-oestrogen 20 mg daily p.o. Competes with 























Progestin 80–160 mg daily p.o. in single 
or divided doses 
Cellular action not fully 
understood 




ER, oestrogen receptor; i.m., intramuscular; p.o., oral. 
 
 
Table 2  
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Key hormonal therapies in prostate cancer 
Drug Type Dose/route Mode of action 
Goserelin LHRHa agonist 3.6 mg every 28 days or 10.8 
mg every 3 12 weeksmonths 
s.c. 
Reduced pituitary 
production of LH and 
FSH 
Leuprorelin LHRHa agonist 3.75 mg every 28 days s.c. or 
i.m or 11.25 mg every 3 3 
monthsmonths – s.c./i.m. 
Reduced pituitary 




240 mg then 80 mg every 28 
days s.c. 
Reduced pituitary 




50 mg (combination dose) or 





Corticosteroid 5–10 mg daily p.o. Adrenal suppression 
Dexamethasone 
(unlicensed) 






1000 mg daily p.o. (with 
prednisolone 5 mg twice once or 
twice daily p.o.) 
Reduced androgen 
production within 
adrenal glands and 
prostate cancer cells 
Enzalutamide AR inhibitor 160 mg daily p.o. Competitive AR 
inhibition, block of AR 
translocation to the 
nucleus 
Apalutamide AR inhibitor 2460 mg daily p.o. Competitive AR 
inhibition, block of AR 
translocation to the 
nucleus 
 
AR, androgen receptor; FSH, follicle-stimulating hormone; i.m., intramuscular; LH, luteinizing hormone; LHRH, luteinizing hormone-
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Figure 1  
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To test your knowledge based on the article you have just read, please complete the questions below. The 





Question 1  
 
A 62-year-old man presented acutely with urinary retention, thoracic back pain and decreased mobility.  
On clinical examination, there was a suprapubic mass, a hard irregular prostate and decreased power in 
the lower limbs.  
 
Investigations 
•Prostatic specific antigen 160 microgram/litre (<4)  
•Plain X-rays of the back showed multiple sclerotic lesions throughout the thoracic spine 
•MR scanning of the spine showed metastatic spinal cord compression at multiple levels including T5 
What is the most appropriate hormonal therapy to use, in addition to the standard management of 
A Start single-agent bicalutamide 150 mg daily 
B Start bicalutamide 50 mg daily and give goserelin 3.6 mg s.c. in a week’s time 
C Start degaralix 240 mg s.c. and give a further injection of 80 mg in 4 weeks’ time 
D Start bicalutamide 50 mg o.d. and give goserelin 3.6 mg s.c. immediately 
E Start degaralix 240 mg s.c. and add abiraterone 1000 mg o.d. with prednisolone 5 mg daily in a 
week’s time 
 
Correct answer: C. Degarelix 
 
Question 2  
 
A 65-year-old woman presented with a lump in the right breast. Examination and investigations 
confirmed this as a carcinoma with a high level of expression of both oestrogen and progesterone 
receptors. The tumour was large and in a small breast and, to avoid a mastectomy, the decision was 
taken to reduce the size by systemic therapy prior to surgery with a 
wide local excision.  
 
What is an appropriate therapeutic hormonal intervention to achieve this? 
 
A Gonadotrophin-releasing hormone agonists 
B Chemotherapy 
C Aromatase inhibitors 
D Progesterone receptor antagonists 
E A selective oestrogen receptor modulator 
 
Correct answer: E. Aromatase inhibitors (C) is the most appropriate agent to use in this situation and 
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